COHANCE LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of COHANCE LIFESCIENCES have increased by 13.91% YoY .
The Earnings Per Share (EPS) of COHANCE LIFESCIENCES has decreased by -10.77 % YoY. |
||
COHANCE LIFESCIENCES Last 5 Annual Financial Results
[BOM: 543064|NSE : COHANCE]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,198 Cr | ₹1,051 Cr | ₹1,340 Cr | ₹1,320 Cr | ₹1,010 Cr |
| Expenses | ₹822 Cr | ₹646 Cr | ₹766 Cr | ₹739 Cr | ₹567 Cr |
| Operating Profit (Excl OI) | ₹375 Cr | ₹406 Cr | ₹574 Cr | ₹582 Cr | ₹443 Cr |
| Other Income | ₹59 Cr | ₹62 Cr | ₹46 Cr | ₹92 Cr | ₹14 Cr |
| Interest | ₹12 Cr | ₹7.45 Cr | ₹13 Cr | ₹8.53 Cr | ₹12 Cr |
| Depreciation | ₹77 Cr | ₹55 Cr | ₹48 Cr | ₹39 Cr | ₹32 Cr |
| Profit Before Tax | ₹344 Cr | ₹406 Cr | ₹560 Cr | ₹668 Cr | ₹468 Cr |
| Profit After Tax | ₹265 Cr | ₹300 Cr | ₹411 Cr | ₹454 Cr | ₹362 Cr |
| Consolidated Net Profit | ₹268 Cr | ₹300 Cr | ₹411 Cr | ₹454 Cr | ₹362 Cr |
| Earnings Per Share (Rs) | ₹10.52 | ₹11.79 | ₹16.16 | ₹17.83 | ₹14.23 |
| PAT Margin (%) | 22.11 | 28.56 | 30.66 | 34.35 | 35.89 |
| ROE(%) | 14.20 | 15.87 | 25.21 | 33.52 | 35.78 |
| ROCE(%) | 18.44 | 21.22 | 33.41 | 45.92 | 40.76 |
| Total Debt/Equity(x) | 0.05 | 0.02 | 0.04 | 0.06 | 0.12 |
Key Financials |
||
| Market Cap | : | ₹ 16,616.3 Cr |
| Revenue (TTM) | : | ₹ 2,268.6 Cr |
| Net Profit(TTM) | : | ₹ 150.1 Cr |
| EPS (TTM) | : | ₹ 3.9 |
| P/E (TTM) | : | 110.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| COHANCE LIFESCIENCES | 2.2% | 3.3% | -55.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 7.4% | 14.5% |
| DIVIS LABORATORIES | 6.4% | 8.3% | 0.7% |
| TORRENT PHARMACEUTICALS | 2.1% | 8.7% | 47.7% |
| CIPLA | 0.5% | 3.6% | -5.6% |
| DR REDDYS LABORATORIES | -7.6% | -2.2% | -5.8% |
| MANKIND PHARMA | 1.7% | 6.4% | 4% |
| LUPIN | 0.5% | 7.7% | 26.3% |
| ZYDUS LIFESCIENCES | -1.3% | 2.7% | 13.2% |
COHANCE LIFESCIENCES Revenues
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | 13.91 % |
| 5 Yr CAGR | 4.36 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,198 Cr | 13.91 | |
| Mar2024 | ₹1,051 Cr | -21.56 | |
| Mar2023 | ₹1,340 Cr | 1.52 | |
| Mar2022 | ₹1,320 Cr | 30.75 | |
| Mar2021 | ₹1,010 Cr | - | |
COHANCE LIFESCIENCES Operating Profit
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | -7.54 % |
| 5 Yr CAGR | -4.07 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹375 Cr | -7.54 | |
| Mar2024 | ₹406 Cr | -29.32 | |
| Mar2023 | ₹574 Cr | -1.30 | |
| Mar2022 | ₹582 Cr | 31.31 | |
| Mar2021 | ₹443 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -18.83 % |
| 5 Yr CAGR | -8.07 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 31.33% | -18.83 | |
| Mar2024 | 38.6% | -9.90 | |
| Mar2023 | 42.84% | -2.77 | |
| Mar2022 | 44.06% | 0.43 | |
| Mar2021 | 43.87% | - | |
COHANCE LIFESCIENCES Profit After Tax
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | -10.79 % |
| 5 Yr CAGR | -7.27 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹268 Cr | -10.79 | |
| Mar2024 | ₹300 Cr | -26.99 | |
| Mar2023 | ₹411 Cr | -9.37 | |
| Mar2022 | ₹454 Cr | 25.24 | |
| Mar2021 | ₹362 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -22.58 % |
| 5 Yr CAGR | -11.41 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 22.11 % | -22.58 | |
| Mar2024 | 28.56 % | -6.85 | |
| Mar2023 | 30.66 % | -10.74 | |
| Mar2022 | 34.35 % | -4.29 | |
| Mar2021 | 35.89 % | - | |
COHANCE LIFESCIENCES Earnings Per Share (EPS)
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | -10.77 % |
| 5 Yr CAGR | -7.27 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹11 | -10.77 | |
| Mar2024 | ₹12 | -27.04 | |
| Mar2023 | ₹16 | -9.37 | |
| Mar2022 | ₹18 | 25.30 | |
| Mar2021 | ₹14 | - | |
COHANCE LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | -13.10 % |
| 5 Yr CAGR | -17.99 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 18.44% | -13.10 | |
| Mar2024 | 21.22% | -36.49 | |
| Mar2023 | 33.41% | -27.24 | |
| Mar2022 | 45.92% | 12.66 | |
| Mar2021 | 40.76% | - | |
COHANCE LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹434.3 |
| Current MarketCap | : | ₹ 16,616.3 Cr |
| Updated EOD on | : | Jul 15,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| COHANCE LIFESCIENCES | 2.2% |
3.3% |
-55.9% |
| SENSEX | 0.9% |
2.2% |
-7.5% |
COHANCE LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 400 MIDSMALLCAP INDEX | 2.8% | 4.9% | 3.3% |
| BSE 250 SMALLCAP INDEX | 2.8% | 5.1% | 1.1% |
| BSE SMALLCAP SELECT INDEX | 2.7% | 3.9% | 6.3% |
| BSE HEALTHCARE | 2.6% | 6.5% | 12.4% |
| BSE 1000 | 1.7% | 3.2% | -1.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 3.1% | 6.6% | 16% |
| NIFTY SMALLCAP 100 | 3.1% | 6.4% | 2.1% |
| NIFTY SMALLCAP 50 | 3% | 6.8% | 4.7% |
| NIFTY SMALLCAP 500 | 2.9% | 5.9% | NA |
| NIFTY SMALLCAP 250 | 2.8% | 6% | 2.1% |
You may also like the below Video Courses
FAQ about COHANCE LIFESCIENCES Financials
How the annual revenues of COHANCE LIFESCIENCES have changed ?
The Revenues of COHANCE LIFESCIENCES have increased by 13.91% YoY .
How the Earnings per Share (EPS) of COHANCE LIFESCIENCES have changed?
The Earnings Per Share (EPS) of COHANCE LIFESCIENCES has decreased by -10.77 % YoY .
Check out Intrinsic Value of Peers of COHANCE LIFESCIENCES
Compare Stock Analytics of Peers of COHANCE LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
